** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** SCCY has announced the new CPX Red ...
CPX-351 showed a 49% CR/CRi rate in older patients with secondary or high-risk AML, with 67% achieving MRD negativity. Early mortality was higher, and fewer patients underwent allo-HSCT compared to ...
** When you buy products through the links on our site, we may earn a commission that supports NRA's mission to protect, preserve and defend the Second Amendment. ** When Joe Roebuck established his ...
SAN DIEGO, California — A novel liposomal formulation of cytarabine and daunorubicin, known as CPX-351 (Vyxeos, Jazz Pharmaceuticals), has again been shown to be superior to a standard version of this ...
Liposomal daunorubicin and cytarabine (CPX-351) was effective in relapsed acute myeloid leukemia, but long-term follow-up is needed to determine the extent of the agent's cardiotoxicity. In a study of ...
IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A subset analysis of a phase 2 study. First-in class selective AXL ...
PRINCETON, N.J.--(BUSINESS WIRE)--Celator Pharmaceuticals today announced positive clinical data in elderly patients with newly-diagnosed acute myeloid leukemia (AML) treated with CPX-351 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results